Tumor Development Is Retarded in Mice Lacking the Gene for Urokinase-Type Plasminogen Activator or Its Inhibitor, Plasminogen Activator Inhibitor-1

In vivo tumor progression in mice with targeted deficiencies in urokinase-type plasminogen activator (UPA −/− ) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1 −/− ) , was studied using a fibrosarcoma tumor model. Murine T241 fibrosarcoma cells were s.c. implanted into three groups of mice with the following genotypes, wild-type ( WT ), UPA −/− , and PAI-1 −/− . A significantly diminished primary tumor growth in UPA −/− and PAI-1 −/− mice occurred, relative to WT mice. Tumors in UPA −/− and PAI-1 −/− mice displayed lower proliferative and higher apoptotic indices and displayed a different neovascular morphology, as compared with WT mice. These results are consistent with the decreased growth rates of this tumor in these gene-deleted mice. Immunohistochemical analyses of the tumors revealed a decrease in vascularity and vascular endothelial growth factor expression only in tumors in PAI-1 −/− mice. Analyses of the relative extents of corneal angiogenesis in these same animals, induced by basic fibroblast growth factor, corroborated the resistance of PAI-1 −/− mice to neovascularization. The results obtained suggest that the host fibrinolytic system plays an important role in tumor growth in this model. Alterations in host expression of components of this system may alter tumor growth and dissemination by affecting the balance between tumor cell death and proliferation, as well as extracellular matrix changes needed for invasiveness and angiogenesis.